Cargando…

A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro

We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show he...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Mary Hongying, Porritt, Rebecca A., Rivas, Magali Noval, Krieger, James M, Ozdemir, Asli Beyza, Garcia, Gustavo, Arumugaswami, Vaithilingaraja, Fries, Bettina C., Arditi, Moshe, Bahar, Ivet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/
https://www.ncbi.nlm.nih.gov/pubmed/33269352
http://dx.doi.org/10.1101/2020.11.24.395079
_version_ 1783617696511819776
author Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
author_facet Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
author_sort Cheng, Mary Hongying
collection PubMed
description We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif, and in particular its PRRA insert, to inhibit infection by blocking the access of host cell proteases, TMPRSS2 or furin, to the cleavage site. The high affinity of 6D3 for the furin-cleavage site originates from a poly-acidic segment at its heavy chain CDR2, a feature shared with SARS-CoV-2-neutralizing mAb 4A8. The affinity of 6D3 and 4A8 for this site points to their potential utility as therapeutics for treating COVID-19, MIS-C, or common cold caused by human coronaviruses (HCoVs) that possess a furin-like cleavage site.
format Online
Article
Text
id pubmed-7709177
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-77091772020-12-03 A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet bioRxiv Article We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif, and in particular its PRRA insert, to inhibit infection by blocking the access of host cell proteases, TMPRSS2 or furin, to the cleavage site. The high affinity of 6D3 for the furin-cleavage site originates from a poly-acidic segment at its heavy chain CDR2, a feature shared with SARS-CoV-2-neutralizing mAb 4A8. The affinity of 6D3 and 4A8 for this site points to their potential utility as therapeutics for treating COVID-19, MIS-C, or common cold caused by human coronaviruses (HCoVs) that possess a furin-like cleavage site. Cold Spring Harbor Laboratory 2020-11-24 /pmc/articles/PMC7709177/ /pubmed/33269352 http://dx.doi.org/10.1101/2020.11.24.395079 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Cheng, Mary Hongying
Porritt, Rebecca A.
Rivas, Magali Noval
Krieger, James M
Ozdemir, Asli Beyza
Garcia, Gustavo
Arumugaswami, Vaithilingaraja
Fries, Bettina C.
Arditi, Moshe
Bahar, Ivet
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_full A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_fullStr A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_full_unstemmed A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_short A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
title_sort monoclonal antibody against staphylococcal enterotoxin b superantigen inhibits sars-cov-2 entry in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/
https://www.ncbi.nlm.nih.gov/pubmed/33269352
http://dx.doi.org/10.1101/2020.11.24.395079
work_keys_str_mv AT chengmaryhongying amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT porrittrebeccaa amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT rivasmagalinoval amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT kriegerjamesm amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT ozdemiraslibeyza amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT garciagustavo amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arumugaswamivaithilingaraja amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT friesbettinac amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arditimoshe amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT baharivet amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT chengmaryhongying monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT porrittrebeccaa monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT rivasmagalinoval monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT kriegerjamesm monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT ozdemiraslibeyza monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT garciagustavo monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arumugaswamivaithilingaraja monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT friesbettinac monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT arditimoshe monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro
AT baharivet monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro